Strong operational momentum at Oxford BioMedica (OXB), as evidenced by its interim maiden operating profit of £9.4m (vs a loss of £2.2m in H117), highlights the strength in the company’s diversified business model. We continue to expect ongoing growth in the top line, driven in the near term by the commercial ramp-up of Kymriah (Novartis), the progression of Bioverativ’s haemophilia products to the clinic and the rapid advancement of its partnered products with Orchard
09 Nov 2018
Oxford BioMedica - Diversified strategy showing its strength
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Oxford BioMedica - Diversified strategy showing its strength
Oxford BioMedica plc (OXB:LON) | 202 -4.1 (-1.0%) | Mkt Cap: 202.5m
- Published:
09 Nov 2018 -
Author:
Dr Daniel Wilkinson -
Pages:
10
Strong operational momentum at Oxford BioMedica (OXB), as evidenced by its interim maiden operating profit of £9.4m (vs a loss of £2.2m in H117), highlights the strength in the company’s diversified business model. We continue to expect ongoing growth in the top line, driven in the near term by the commercial ramp-up of Kymriah (Novartis), the progression of Bioverativ’s haemophilia products to the clinic and the rapid advancement of its partnered products with Orchard